Last Updated : April 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Spriafil | Posaconazole | Aspergillus and Candida infections | Do not list | Complete | ||
| VFEND | Voriconazole | Aspergillosis, Invasive | Withdrawn | |||
| VFEND | Voriconazole | Aspergillosis, Invasive | List with clinical criteria and/or conditions | Complete | ||
| Olumiant | baricitinib | Arthritis, Rheumatoid | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rinvoq | upadacitinib | Arthritis, Rheumatoid | Reimburse with clinical criteria and/or conditions | Complete | ||
| TBC | filgotinib | Arthritis, Rheumatoid | Withdrawn | |||
| Kevzara | sarilumab | Arthritis, Rheumatoid | Reimburse with clinical criteria and/or conditions | Complete | ||
| Orencia | Abatacept | Arthritis, rheumatoid | List with clinical criteria and/or conditions | Complete | ||
| Simponi I.V. | Golimumab | Arthritis, rheumatoid | List with criteria/condition | Complete | ||
| Actemra | Tocilizumab | Arthritis, rheumatoid | List with criteria/condition | Complete |
Last Updated : April 28, 2024